Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 108 of 151

  1. R2810-ONC-2268

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Keratoconjunctivitis Sicca

    phase 2 small molecule completed

    2 trials

  3. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Chronic Graft-versus-host Disease

    phase 2 small molecule completed

    1 trial

  4. R3767-ONC-2208

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  5. R3767-ONC-2266

    Lacuna Pharma Pty Ltd

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. R3767-ONC-2466

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  7. R4018-ONC-1721

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  8. R475

    Regeneron UK Limited

    Thermal Injury Pain

    phase 2 small molecule terminated

    1 trial

  9. R5458-ONC-1826

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  10. R5458-ONC-2257

    Lacuna Pharma Pty Ltd

    High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma

    phase 2 small molecule active

    1 trial

  11. R5458-ONC-2274

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  12. R7508-DVT-2360

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 2 small molecule active

    1 trial

  13. R788

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  14. R7999 matching placebo, REGN7999

    Lacuna Pharma Pty Ltd

    Non-transfusion dependent beta-thalassemia (NTDT), Beta-thalassemia Resultant Iron overload (IOL)

    phase 2 small molecule active

    1 trial

  15. R906289 Monosodium (R289 Na)

    RIGEL PHARMACEUTICALS INC

    Low Risk Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  16. R926112

    RIGEL PHARMACEUTICALS INC

    Rhinitis, Allergic, Seasonal

    phase 2 small molecule completed

    1 trial

  17. R932333

    RIGEL PHARMACEUTICALS INC

    Lupus Erythematosus, Discoid

    phase 2 small molecule completed

    1 trial

  18. R9933-DVT-2308

    Lacuna Pharma Pty Ltd

    Venous Thromboembolism

    phase 2 small molecule active

    1 trial

  19. RAD001

    Ultragenyx UK Limited

    PTEN Gene Mutation

    phase 2 small molecule completed

    1 trial

  20. RAP-219

    Rapport Therapeutics

    Focal Epilepsy

    phase 2 small molecule active

    1 trial

  21. RAP-219

    Rapport Therapeutics

    Focal Onset Seizures

    phase 2 small molecule completed

    1 trial

  22. RAP-219

    Rapport Therapeutics

    Bipolar 1 Disorder

    phase 2 small molecule active

    1 trial

  23. RAVICTI 1.1 g/ml oral liquid

    Pari Pharma GmbH

    Pyruvate dehydrogenase deficiency

    phase 2 small molecule active

    1 trial

  24. RBP-6000

    Indivior Pty Ltd

    Opioid Related Disorder

    phase 2 small molecule completed

    1 trial

  25. RBP-6300

    Indivior Pty Ltd

    Opioid Related Disorder

    phase 2 small molecule completed

    1 trial

  26. RBP-8000 100 mg

    Indivior Pty Ltd

    Opioid Dependence

    phase 2 small molecule completed

    1 trial

  27. RC02T001

    Lacuna Pharma Pty Ltd

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  28. RC03T001

    Lacuna Pharma Pty Ltd

    Stable Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  29. RC04T001

    Lacuna Pharma Pty Ltd

    Chronic hepatitis D virus infection

    phase 2 small molecule active

    1 trial

  30. RC48- ADC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance

    phase 2 small molecule active

    1 trial

  31. RC48-ADC

    Chinese University of Hong Kong

    Muscle Invasive Bladder Carcinoma

    phase 2 small molecule active

    1 trial

  32. RD14-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 mab active

    1 trial

  33. RE-021 (Sparsentan)

    Travere Therapeutics

    Focal Segmental Glomerulosclerosis

    phase 2 small molecule completed

    1 trial

  34. REC-1245

    RECURSION PHARMACEUTICALS, INC.

    Unresectable

    phase 2 small molecule active

    1 trial

  35. REC-3964

    RECURSION PHARMACEUTICALS, INC.

    Recurrent Clostridioides Difficile Infection

    phase 2 small molecule terminated

    1 trial

  36. REC-4881

    RECURSION PHARMACEUTICALS, INC.

    Familial Adenomatous Polyposis

    phase 2 small molecule active

    1 trial

  37. REC-4881

    RECURSION PHARMACEUTICALS, INC.

    AXIN1 Gene Mutation

    phase 2 small molecule terminated

    1 trial

  38. REC-994

    RECURSION PHARMACEUTICALS, INC.

    Cerebral Cavernous Malformation

    phase 2 small molecule completed

    1 trial

  39. REFRaME-P1

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 other active

    1 trial

  40. REGEND001 cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  41. REGN1033 (SAR391786)

    Regeneron UK Limited

    Sarcopenia

    phase 2 small molecule completed

    1 trial

  42. REGN10597

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  43. REGN10933+REGN10987 combination therapy

    Regeneron UK Limited

    COVID-19

    phase 2 small molecule completed

    2 trials

  44. REGN13335

    Regeneron UK Limited

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  45. REGN14256

    Regeneron UK Limited

    SARS-CoV-2

    phase 2 small molecule terminated

    1 trial

  46. REGN1500 250 mg SC/15 mg/kg IV/450 mg SC

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  47. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  48. REGN1908-1909

    Regeneron UK Limited

    Cat Allergy

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.